Composition:

Blokatens HCT 5 mg/160 mg/12.5 mg film-coated tablets 
Each film-coated tablet contains Amlodipine besylate 6.934 mg (equivalent to Amlodipine 5 mg), 
Valsartan 160 mg, Hydrochlorothiazide 12.5 mg. 

Blokatens HCT 10 mg/160 mg/12.5 mg film-coated tablets 
Each film-coated tablet contains Amlodipine besylate 13.869 mg (Equivalent to Amlodipine 10 mg), Valsartan 160 mg, Hydrochlorothiazide 12.5 mg. 

Blokatens HCT 5 mg/160 mg/25 mg film-coated tablets 
Each film-coated tablet contains Amlodipine besylate 6.934 mg (Equivalent to Amlodipine 5 mg), Valsartan 160 mg, Hydrochlorothiazide 25 mg. 

Blokatens HCT 10 mg/160 mg/25 mg film-coated tablets 
Each film-coated tablet contains Amlodipine besylate 13.869 mg (Equivalent to Amlodipine 10 mg), Valsartan 160 mg, Hydrochlorothiazide 25 mg. 

Therapeutic indications: 

Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan, and hydrochlorothiazide (HCT). 
Taken either as three single-component formulations or as a dual-component and a single-component formulation.